skip to main content

Alternative Inhaled Anti-Pseudomonal — SCE Infectious Diseases MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRespiratory InfectionAlternative Inhaled Anti-PseudomonalSCE Infectious Diseases

A 50-year-old man with chronic Pseudomonas colonisation of bronchiectatic airways develops Tobramycin-resistant Pseudomonas after 2 years of inhaled Tobramycin. What alternative inhaled anti-pseudomonal agents are available?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: DInhaled Colistin (Colistimethate sodium) or inhaled Aztreonam lysine — both are licensed alternatives when Tobramycin resistance develops

When inhaled Tobramycin resistance develops in chronic Pseudomonas bronchiectasis/CF, alternatives include: inhaled Colistin (Colistimethate sodium — nebulised or dry powder inhaler) and inhaled Aztreonam lysine (Cayston — nebulised). Both achieve high local airway concentrations far exceeding systemic MICs. Alternating between inhaled agents (e.g. monthly cycling between Tobramycin and Colistin) may reduce resistance development. IV Meropenem cannot be nebulised (wrong formulation). Sputum culture with susceptibility testing should guide inhaled agent selection.

Reference: BTS 2019 – Bronchiectasis; CF Trust 2024; NICE NG117